Список литературы к Главе 20

1. Hallek M., Fischer K., Fingerle­Rowson G., Fink A.M., Busch R., Mayer J. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376. P. 1164–1174.

2. Stilgenbauer S., Schnaiter A., Paschka P., Zenz T., Rossi M., Dohner K. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123. P. 3247–3254.

3. Fischer K., Cramer P., Busch R., Böttcher S., Bahlo J., Schubert J. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2012. Vol. 30. P. 3209–3216.

4. Hallek M., Cheson B.D., Catovsky D., Caligaris­Cappio F., Dighiero G., Dohner H. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute­Working Group 1996 guidelines // Blood. 2008. Vol. 111. P. 5446–5456.

5. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343. P. 1910–1916.

6. Zenz T., Eichhorst B., Busch R., Denzel T., Häbe S., Winkler D. et al. TP53 mutation and survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2010. Vol. 28. P. 4473–4479.

7. Rossi D., Cerri M., Deambrogi C., Sozzi E., Cresta S., Rasi S. et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness // Clin. Cancer Res. 2009. Vol. 15. P. 995–1004.

8. Zenz T., Krober A., Scherer K., Habe S., Buhler A., Benner A. et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long­term follow­up // Blood. 2008. Vol. 112. P. 3322–3329.

9. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V. et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage // Blood. 2009. Vol. 114. P. 5307–5314.

10. Zainuddin N., Murray F., Kanduri M., Gunnarsson R., Smedby K.E., Enblad G. et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia // Leuk. Res. 2011. Vol. 35. P. 272–274.

11. Dicker F., Herholz H., Schnittger S., Nakao A., Patten N., Wu L. et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype // Leukemia. 2009. Vol. 23. P. 117–124.

12. Zenz T., Häbe S., Denzel T., Mohr J., Winkler D., Bühler A. et al. Detailed analysis of p53 pathway defects in fludarabine­refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53­p21 dysfunction, and miR34a in a prospective clinical trial // Blood. 2009. Vol. 114. P. 2589–2597.

13. Stengel A., Kern W., Haferlach T., Meggendorfer M., Fasan A., Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases // Leukemia. 2017. Vol. 31. P. 705–711.

14. Gonzalez D., Martinez P., Wade R., Hockley S., Oscier D., Matutes E. et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial // J. Clin. Oncol. 2011. Vol. 29. P. 2223–2229.

15. Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J.F., Munir T. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open­label, phase 2 study // Lancet Oncol. 2016. Vol. 17. P. 768–778.

16. O’Brien S., Jones J.A., Coutre S.E., Mato A.R., Hillmen P., Tam C. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE­17): a phase 2, open­label, multicentre study // Lancet Oncol. 2016. Vol. 17. P. 1409–1418.

17. Brown J.R., Byrd J.C., Coutre S.E., Benson D.M., Flinn I.W., Wagner­Johnston N.D. et al. Idelalisib, an inhibitor of phosphatidylinositol 3­kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia // Blood. 2014. Vol. 123. P. 3390–3397.

18. Pospisilova S., Gonzalez D., Malcikova J., Trbusek M., Rossi D., Kater A.P. et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia // Leukemia. 2012. Vol. 26. P. 1458–1461.

19. Malcikova J., Stano­Kozubik K., Tichy B., Kantorova B., Pavlova S., Tom N. et al. Detailed analysis of therapy­driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia // Leukemia. 2015. Vol. 29. P. 877–885.

20. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia // Cell. 2013. Vol. 152. P. 714–726.

21. Nadeu F., Delgado J., Royo C., Baumann T., Stankovic T., Pinyol M. et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia // Blood. 2016. Vol. 127. P. 2122–2130.

22. Rossi D., Khiabanian H., Spina V., Ciardullo C., Bruscaggin A., Famà R. et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia // Blood. 2014. Vol. 123. P. 2139–2147.

23. Zenz T., Habe S., Denzel T., Winkler D., Dohner H., Stilgenbauer S. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance // Leukemia. 2008. Vol. 22. P. 2257–2258.